Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. - Wikidata - wikimedia - TriplyDB

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

http://www.wikidata.org/entity/Q33769821

about

Tumor-Specific Peptide, Selected from a Phage Peptide Library, Enhances Antitumor Activity of Lactaptin Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study Identification of novel prognostic indicators for triple-negative breast cancer patients through integrative analysis of cancer genomics data and protein interactome data.Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer pa Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation.AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.Salicylate •Phenanthroline copper (II) complex induces apoptosis in triple-negative breast cancer cells.ERβ1 inhibits metastasis of androgen receptor-positive triple-negative breast cancer by suppressing ZEB1.Low expression of PinX1 is associated with malignant behavior in basal-like breast cancer Integrative analysis of genomic alterations in triple-negative breast cancer in association with homologous recombination deficiency.Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients.Transcriptomic immunologic signature associated with favorable clinical outcome in basal-like breast tumors Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis.The fate of BRCA1-related germline mutations in triple-negative breast tumors.AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.Down regulation of ADAM33 as a Predictive Biomarker of Aggressive Breast Cancer BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.Relationship between mammographic calcifications and the clinicopathologic characteristics of breast cancer in Western China: a retrospective multi-center study of 7317 female patients.HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology.Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.Vitamin D compounds inhibit cancer stem-like cells and induce differentiation in triple negative breast cancer.Triple negative breast cancer: the kiss of death.Olaparib for the treatment of breast cancer.Resistin potentiates chemoresistance and stemness of breast cancer cells: Implications for racially disparate therapeutic outcomes.Adaptive immunity programmes in breast cancer.Triple Negative Breast Cancer at the University Hospital Mohammed VI – Oujda Strategies to avoid treatment-induced lineage crisis in advanced prostate cancer.Advancement of mass spectrometry-based proteomics technologies to explore triple negative breast cancer.Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials.Germline Mutations in Triple-Negative Breast Cancer.Post-nano strategies for drug delivery: Multistage porous silicon microvectors.YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway.Peri-foci adipose-derived stem cells promote chemoresistance in breast cancer Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models.Identification of candidate genes associated with triple negative breast cancer.

P2860

Q28553463-7DDE31B1-E50A-4A23-9718-5891E7E095BF Q29248323-1FF86463-88F0-43FA-855A-87515D155811 Q31134060-9D0F41D3-3216-41F1-B664-E5F8D64E30FC Q31160308-F9B8CA4C-DEA5-4C4D-82CA-AB4622DDDC6B Q33577449-B4A58F0C-9879-4567-B357-8B0C7D344FAB Q33667940-573CD471-C615-4AA2-8CD4-D3B0904A3C72 Q33728161-E868FD5A-97DA-4818-B30A-46D5344EEA95 Q33768248-8D8097C0-D679-44D5-B825-F18836B71B5A Q33858225-240C15ED-1E41-4AA0-BD4B-C89703AA78AC Q33880847-CE1754E3-7164-4E3B-8E74-AFFB12B2A6BC Q36265028-1ED6DEC3-ABB0-4160-BE06-FADFC11D5574 Q36289931-505B7E05-D008-4480-A85C-413345B22644 Q36363060-6C3DA4B0-A562-4F96-BCA5-EA622D24AAC7 Q37465641-C308A1A2-3C24-4AFF-B228-35005A52EFEF Q37596828-ED211734-1BDB-40FE-A142-51C10D7BDC13 Q37629545-45F9D36A-3ED0-4C1B-8E5F-F5D8E89F35F3 Q37630473-34BF5D25-2925-4334-8216-51A13E0C7984 Q37644990-66209EA0-9AD4-4DFE-B210-3B999D882997 Q37704788-CE2EA92C-A23A-4A93-B8BF-B09D666399F6 Q38617840-B0453FEC-3B54-4B75-8484-125F557EEB09 Q38640378-8475E375-54CF-4A51-9833-25A629FD81D8 Q38645153-27BE1E5D-A572-4142-8FB7-C0F043765499 Q38646090-05CAB9C8-C519-4181-9806-542B6C3BBCE8 Q38718686-6A66984F-A3AD-42DA-A596-BE9DCB67B5ED Q38727418-31FDDD3C-977B-4827-B85A-5529A768AA19 Q38818744-46BE9919-20CA-426D-9140-86592336D3EB Q38843992-DA563C02-E9A4-407F-AD58-97560F2C5F75 Q38902610-1999D1AB-A63D-4AEF-B5D0-367018CD3850 Q38937896-130B6226-FC12-4F3D-8938-88C5979CC74C Q38940118-B5B49799-5ECD-43AB-8892-39C50EDE07E0 Q39016544-3EAE4F54-C27E-4E6D-9C0B-CEC15826024E Q39021766-B654E457-A170-4137-B9BE-2FE9B48971F2 Q39149219-B40D8CA7-7FD7-44C8-A1E8-0CFC955E5397 Q39370774-7A547153-7614-41FE-BAE3-14954295CCAC Q39410383-656EE805-92A4-4F76-B638-F0A1500C6280 Q40980456-0C64590C-EED1-4FFD-8A10-22CA95C12E34 Q41163628-32EE7185-A2D7-4433-90DB-1327CBACE61B Q41233528-F728E8F0-6A03-4EBA-8345-D249CC441CC9 Q41634144-FB69C0CC-776E-41F3-92CC-2579E573DD69 Q41659323-D5E95E00-465B-488A-8DC3-3DAE1D01E1D8

P2860

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

http://www.wikidata.org/entity/Q33769821

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@ast

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@en

type

label

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@ast

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@en

prefLabel

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@ast

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@en

P1433

Q33769821-EC3CBFBE-8F78-4DE5-95A0-51680427893B

P1476

Q33769821-0D55571E-3D7C-4D21-8AD2-FB1CD1FC4EAD

P2093

Q33769821-116699BB-62F2-453C-967C-B73A4EF3D2DA

Q33769821-9A524704-99A0-4392-BCF6-22E4EEBE30C8

Q33769821-C3721087-BEC7-4AA6-83B0-AF705E212B75

Q33769821-FFCC9BE6-2FCB-4A4D-BD22-A32697D592BA

P2860

Q33769821-0067C1A9-8BB2-4592-B854-5F26AF65570A

Q33769821-050346EB-968C-4701-B9FC-8C956F364AB0

Q33769821-05D2A5FE-BED5-46FE-A03F-897A492FF5CE

Q33769821-05F86E05-3103-4A6D-BADB-FA8006AD100B

Q33769821-064F28C5-E2F7-4151-B6EF-16C43C05CE39

Q33769821-0792C855-7856-4108-A97B-1CCB5AA1AC1B

Q33769821-081A9CB4-04F2-45E0-8177-F7B98D77F472

Q33769821-083CE368-0E32-42E8-A61E-CEB0399FD5A9

Q33769821-0B9BC56B-A114-4C58-9C65-0578088F47BB

Q33769821-0E784F52-ADAC-410B-AA0B-0DBE311FA963

P304

Q33769821-16FCB368-4CAB-4F2F-A8EC-76A4EDED2AE0

P31

Q33769821-0b7bf682-a068-4e97-9a76-6cc6a3fc0987

Q33769821-3AF3B2DE-9F48-4D95-8840-39CE2FD7FDE9

P356

Q33769821-2D3A3261-C5B8-485A-B8F7-5415DC79A2B4

P407

Q33769821-D1183E88-9B27-4803-B0E1-674299EEB9BB

P433

Q33769821-279E2FC1-C0AA-4173-B99E-8D9ED9F8EF87

P478

Q33769821-BEA5B677-7D4D-47A1-830A-65341FBC1F39

P50

Q33769821-2964A59F-BC6A-4912-9872-CEA13C66D3BE

Q33769821-746961E1-F88A-479A-A787-99192D0E12D2

P577

Q33769821-23366003-D293-4707-B8BB-E9A66413060B

P698

Q33769821-B8F17AC9-1A9C-48EE-95E0-88CF093E8D00

P932

Q33769821-73135BB6-340D-4E19-BD0B-312C66791ECF

P356

NRCLINONC.2016.66

P1433

Nature Reviews Clinical Oncology

P1476

Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.

@en

P2093

Giampaolo Bianchini

http://www.w3.org/2001/XMLSchema#string

Ingrid A Mayer

http://www.w3.org/2001/XMLSchema#string

Luca Gianni

http://www.w3.org/2001/XMLSchema#string

Melinda E Sanders

http://www.w3.org/2001/XMLSchema#string

P2860

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer

Comprehensive molecular portraits of human breast tumours

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

The epithelial-mesenchymal transition generates cells with properties of stem cells

Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer

Activating HER2 mutations in HER2 gene amplification negative breast cancer

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

P304

674-690

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCLINONC.2016.66

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Justin M. Balko

P577

2016-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27184417

http://www.w3.org/2001/XMLSchema#string

P932

5461122

http://www.w3.org/2001/XMLSchema#string